[go: up one dir, main page]

IN2012DN02752A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02752A
IN2012DN02752A IN2752DEN2012A IN2012DN02752A IN 2012DN02752 A IN2012DN02752 A IN 2012DN02752A IN 2752DEN2012 A IN2752DEN2012 A IN 2752DEN2012A IN 2012DN02752 A IN2012DN02752 A IN 2012DN02752A
Authority
IN
India
Prior art keywords
dii4
vegf
binding molecules
binding component
bispecific binding
Prior art date
Application number
Inventor
Borges Eric
Gschwind Andreas
Boucnead Joachim
De Tavernier Evelyn
Kolkman Joost
Merchiers Pascal
Van Hoorick Daine
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN02752(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IN2012DN02752A publication Critical patent/IN2012DN02752A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a DII4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and DII4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same.
IN2752DEN2012 2009-10-02 2010-10-01 IN2012DN02752A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09172137 2009-10-02
EP10175316 2010-09-03
PCT/EP2010/064695 WO2011039370A1 (en) 2009-10-02 2010-10-01 Bispecific binding molecules for anti-angiogenesis therapy

Publications (1)

Publication Number Publication Date
IN2012DN02752A true IN2012DN02752A (en) 2015-09-18

Family

ID=43431796

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2752DEN2012 IN2012DN02752A (en) 2009-10-02 2010-10-01

Country Status (24)

Country Link
US (2) US20110172398A1 (en)
EP (1) EP2483314A1 (en)
JP (2) JP5833009B2 (en)
KR (1) KR20120101375A (en)
CN (2) CN102639566B (en)
AP (1) AP2012006188A0 (en)
AR (1) AR078515A1 (en)
AU (1) AU2010302589A1 (en)
BR (1) BR112012007239A2 (en)
CA (1) CA2775422A1 (en)
CL (1) CL2012000826A1 (en)
EA (1) EA201200548A1 (en)
EC (1) ECSP12011835A (en)
IL (1) IL218542A0 (en)
IN (1) IN2012DN02752A (en)
MA (1) MA33607B1 (en)
MX (1) MX2012003897A (en)
NZ (2) NZ598956A (en)
PE (1) PE20121024A1 (en)
PH (1) PH12012500525A1 (en)
TN (1) TN2012000145A1 (en)
TW (1) TW201124533A (en)
UY (1) UY32920A (en)
WO (1) WO2011039370A1 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5535633B2 (en) 2006-09-29 2014-07-02 オンコメッド ファーマシューティカルズ インコーポレイテッド Compositions and methods for diagnosis and treatment of cancer
JP5646457B2 (en) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulins and uses thereof
JP2011523853A (en) 2008-06-03 2011-08-25 アボット・ラボラトリーズ Dual variable domain immunoglobulins and uses thereof
RU2010153578A (en) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
KR101722961B1 (en) 2009-02-11 2017-04-04 알부메딕스 에이/에스 Albumin variants and conjugates
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY159837A (en) 2009-08-29 2017-02-15 Abbvie Inc Therapeutic dll4 binding proteins
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
ES2700450T3 (en) 2009-10-16 2019-02-15 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
US8748380B2 (en) 2009-10-30 2014-06-10 Novozymes Biopharma Dk A/S Albumin variants
SG183872A1 (en) 2010-03-02 2012-11-29 Abbvie Inc Therapeutic dll4 binding proteins
AU2011249782B2 (en) 2010-05-06 2014-10-02 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
PH12012502406A1 (en) 2010-05-06 2013-02-18 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EP2596362A1 (en) 2010-07-19 2013-05-29 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
EP2596361A1 (en) 2010-07-19 2013-05-29 F.Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
BR112013002578A2 (en) 2010-08-03 2019-05-14 Abbvie Inc. double variable domain immunoglobins and their uses
MX2013002270A (en) 2010-08-26 2013-05-14 Abbvie Inc Dual variable domain immunoglobulins and uses thereof.
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US20130323265A1 (en) * 2010-11-15 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
AU2015268749B2 (en) * 2011-09-23 2017-05-25 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
SI3485903T1 (en) * 2011-09-23 2023-02-28 Mereo Biopharma 5, Inc. Vegf/dll4 binding agents and uses thereof
TW201323442A (en) 2011-11-04 2013-06-16 Novartis Ag Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
CN104159920A (en) 2011-12-30 2014-11-19 艾伯维公司 Dual specific binding proteins directed against il-13 and/or il-17
ES2664328T3 (en) 2012-03-16 2018-04-19 Albumedix A/S Albumin variants
RS62509B1 (en) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
KR20150060686A (en) * 2012-09-28 2015-06-03 베링거 인겔하임 인터내셔날 게엠베하 PHARMACEUTICAL COMBINATIONS COMPRISING DUAL ANGIOPOIETIN-2/Dll4 BINDERS AND ANTI-VEGF AGENTS
CA2883807A1 (en) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
WO2014062659A2 (en) * 2012-10-15 2014-04-24 Oncomed Pharmaceuticals, Inc. Methods of treating ocular diseases
CA2889638A1 (en) * 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
TW202210507A (en) 2012-11-01 2022-03-16 美商艾伯維有限公司 Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
EP3466973A1 (en) * 2012-11-01 2019-04-10 AbbVie Inc. Stable dual variable domain immunoglobulin protein formulations
BR112015010318A2 (en) 2012-11-08 2017-08-22 Albumedix As ALBUMIN VARIANTS
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
TR201910592T4 (en) * 2013-07-09 2019-08-21 Ablbio New double-targeted protein that specifically binds to dll4 and vegf and its use.
US11185583B2 (en) * 2014-02-11 2021-11-30 Albany Medical College Multi-functional mucosal vaccine platform
EP3125937A4 (en) * 2014-04-04 2017-11-01 Oncomed Pharmaceuticals, Inc. Treatment of gastric cancer
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
DK3212233T3 (en) 2014-10-31 2020-07-27 Oncomed Pharm Inc COMBINATION THERAPY FOR TREATMENT OF DISEASE
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016192613A1 (en) * 2015-06-01 2016-12-08 中山大学 Bivalent antibody having single-domain antigen-binding fragment fused to conventional fab fragment
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
TWI746473B (en) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 Single domain antibodies directed against intracellular antigens
WO2017096397A1 (en) * 2015-12-04 2017-06-08 The Regents Of The University Of California Novel antibodies for the treatment of cancers
US10941382B2 (en) * 2016-01-29 2021-03-09 Kyoto University Platelet production promoter and method of producing platelets using same
US11198725B2 (en) * 2017-01-30 2021-12-14 Alexion Pharmaceuticals, Inc. Monovalent anti-properdin antibodies and antibody fragments
CA3090321A1 (en) * 2018-02-05 2019-08-08 Stichting Vu Inverse agonistic anti-us28 antibodies
CN111995686B (en) * 2019-05-27 2022-06-14 兰州大学 A kind of medicine with anti-angiogenesis activity and preparation method thereof
TW202434620A (en) * 2019-07-31 2024-09-01 美商美國禮來大藥廠 Relaxin analogs and methods of using the same
CN110452297B (en) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 Anti-VEGF single domain antibody and its application
WO2022057888A1 (en) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 Bispecific antigen binding molecule specifically binding to vegf and ang-2
CN112535738B (en) * 2020-12-04 2022-09-09 中国科学技术大学 Oxaliplatin conjugate and preparation method and application thereof
BR112023016095A2 (en) * 2021-02-10 2023-11-14 Jiangxi Jemincare Group Co Ltd ANTI-VEGF ANTIBODY AND USE THEREOF
CN115724968B (en) * 2021-08-27 2023-08-08 三优生物医药(上海)有限公司 VEGF binding molecules and uses thereof
EP4436996A4 (en) * 2021-11-24 2025-10-08 Linno Pharmaceuticals Inc VEGF-BINDING PROTEIN AND USE THEREOF
CN116063469B (en) * 2022-08-29 2023-09-22 中山大学 A Zika virus neutralizing nanobody and its preparation method and application
EP4582447A4 (en) * 2022-09-14 2026-01-21 Quaerite Biopharm Res Beijing Co Ltd ANTI-VEGFA ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THEREOF AND USES THEREOF
WO2024106394A1 (en) 2022-11-14 2024-05-23 株式会社Ｃоｇｎａｎо Antibody and method for producing antibody
CN117686722B (en) * 2023-12-20 2024-08-09 内蒙古元牛繁育科技有限公司 S100A4 nano antibody and application thereof
CN117860786B (en) * 2024-03-12 2024-06-04 北京贝来药业有限公司 Pharmaceutical and diagnostic uses of genetically modified mesenchymal stem cells in various diseases
CN120025456B (en) * 2024-03-13 2025-11-07 寻济生物科技（北京）有限公司 VEGFA-resistant fusion construct, and preparation method and application thereof
WO2025212751A1 (en) * 2024-04-02 2025-10-09 Therini Bio, Inc. Multi-specific antigen-binding proteins which bind human fibrin yc or fibrinogen yc domain and vascular endothelial growth factor and methods of use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1589107E (en) 1992-08-21 2010-03-29 Univ Bruxelles IMMUNOGLOBULINS FOR LIGHT CHAINS
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
ES2484966T3 (en) 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Albumin fusion proteins
CA2433877C (en) 2001-01-17 2014-11-18 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
EP2301967A3 (en) 2002-11-08 2011-07-13 Ablynx N.V. Single domain antibodies for nasal administration
KR101025143B1 (en) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 Hydrolytically Stable Maleimide-terminated Polymers
NZ540771A (en) * 2003-01-10 2009-05-31 Ablynx Nv Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
JP2007534631A (en) * 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ Laminin-5γ2 binding peptides, related compositions and uses thereof
AU2003283136A1 (en) 2003-11-07 2005-05-26 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
BRPI0518151A2 (en) 2004-10-13 2009-06-16 Ablynx Nv polypeptides against amyloid-beta, nucleic acid encoding such polypeptide, composition comprising such polypeptide, method for producing a polypeptide and use thereof
US8048418B2 (en) * 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
CA2608770C (en) 2005-05-18 2017-05-30 Ablynx Nv Improved nanobodies against tumor necrosis factor-alpha
CA2960105A1 (en) * 2005-05-20 2006-11-23 Ablynx Nv Single domain vhh antibodies against von willebrand factor
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2630839C (en) 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
JP2009539870A (en) 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド Compositions and methods for modulating angiogenesis
CN101490084A (en) * 2006-06-06 2009-07-22 健泰科生物技术公司 anti-DLL 4 antibodies and methods of use thereof
US7803377B2 (en) 2006-06-06 2010-09-28 Genentech, Inc. Anti-DLL4 antibodies and methods using same
SG174033A1 (en) * 2006-08-07 2011-09-29 Regeneron Pharma Therapeutic methods for treating vascular eye disorders with dll4 antagonists
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
WO2008070513A1 (en) * 2006-12-01 2008-06-12 Alcon Research, Ltd. Modulation of polysialylated neural adhesion molecules (psa-ncam) as a regulator of ocular disease
NO347649B1 (en) 2006-12-14 2024-02-12 Regeneron Pharma Human antibody or antibody fragment that specifically binds human delta-like ligand 4 (hDII4), nucleic acid molecule that codes for such and vector and host-vector systems, as well as method for production, composition and use.
JP2010518839A (en) * 2007-02-21 2010-06-03 アブリンクス エン．ヴェー． Amino acid sequence directed against vascular endothelial growth factor and polypeptides comprising it for treating conditions and diseases characterized by excessive and / or pathological angiogenesis or angiogenesis
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
CN102056945A (en) * 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 Amino acid sequences directed against the Notch pathways and uses thereof
JP5646457B2 (en) * 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulins and uses thereof
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AU2010245011B2 (en) * 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US20110172398A1 (en) * 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy

Also Published As

Publication number Publication date
MX2012003897A (en) 2012-05-08
AR078515A1 (en) 2011-11-16
JP2016026207A (en) 2016-02-12
CA2775422A1 (en) 2011-04-07
TW201124533A (en) 2011-07-16
CN105037542A (en) 2015-11-11
KR20120101375A (en) 2012-09-13
EA201200548A1 (en) 2012-12-28
CL2012000826A1 (en) 2012-10-19
CN102639566B (en) 2015-07-22
US20140120095A1 (en) 2014-05-01
AU2010302589A1 (en) 2012-04-19
CN102639566A (en) 2012-08-15
AP2012006188A0 (en) 2012-04-30
EP2483314A1 (en) 2012-08-08
PH12012500525A1 (en) 2012-11-26
US20110172398A1 (en) 2011-07-14
JP5833009B2 (en) 2015-12-16
WO2011039370A1 (en) 2011-04-07
NZ598956A (en) 2014-07-25
UY32920A (en) 2011-04-29
NZ626302A (en) 2015-09-25
IL218542A0 (en) 2012-05-31
ECSP12011835A (en) 2012-06-29
TN2012000145A1 (en) 2013-09-19
PE20121024A1 (en) 2012-08-10
BR112012007239A2 (en) 2019-09-24
MA33607B1 (en) 2012-09-01
JP2013506411A (en) 2013-02-28

Similar Documents

Publication Publication Date Title
IN2012DN02752A (en)
PH12013500410B1 (en) Vegf-binding molecules
TN2013000390A1 (en) Bispecific binding molecules binding to vegf and ang2
TN2012000144A1 (en) Dll4-binding molecules
PH12014502179A1 (en) Ang2-binding molecules
WO2014004549A3 (en) Anti-mesothelin binding proteins
NZ623607A (en) Anti-gcc antibody molecules and related compositions and methods
MX374128B (en) FORMULATIONS OF SINGLE-DOMAIN ANTIGEN-BINDING MOLECULES.
WO2015108998A3 (en) Cartilage targeting agents and their use
WO2009073533A3 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
WO2013173761A3 (en) St2 antigen binding proteins
WO2013119966A3 (en) Single-chain antibodies and other heteromultimers
TN2013000389A1 (en) BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2
NZ761636A (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
MX2016008478A (en) Novel anti adam17 antibody and its use for the treatment of cancer.